Prime for a buyout15 Jul 2025 08:27
With a 7m MCAP Fusion Antibodies presents itself as a prime target for a buyout by big pharma.
In 2025, there have been many buyouts announced for companies with groundbreaking antibodies and antibody derived components.
Merck & Co. → Verona Pharma
Deal size: $10 billion (≈ $107/share, 23% premium
A COPD-maintenance inhaled antibody therapy approved in 2024—helping offset revenue loss as Keytruda patent expires in 2028
Novartis → Anthos Therapeutics
Deal value: Up to $3.08 billion (≈ $925 M upfront, remaining upon milestones)
Abelacimab is a late‑stage monoclonal antibody against Factor XI for stroke prevention & cancer‑related thrombosis
AstraZeneca → EsoBiotec
Deal value: Up to $1 billion (initial $425 M + milestone payments)
In‑vivo CAR‑T cell therapies delivered via IV to fight cancer/autoimmune—aligns with AstraZeneca’s expanding cell‑therapy ambitions (utilizes antibody-derived components)
Fusion states they’ve served eight of the top 10 global pharmaceutical companies, that group likely includes industry giants such as Pfizer, Novartis, Roche, Merck and AstraZeneca.
Big pharma is prepared to pay huge multiples of Fusions current MCAP to get what they want.
7m is pocket change currently.